HC Wainwright Forecasts Strong Price Appreciation for Delcath Systems (NASDAQ:DCTH) Stock

Delcath Systems (NASDAQ:DCTH) had its price objective upped by research analysts at HC Wainwright from $32.00 to $36.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright‘s price target would suggest a potential upside of 77.60% from the company’s current price.

Other equities analysts have also issued research reports about the stock. BTIG Research upped their price target on shares of Delcath Systems from $21.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday. Weiss Ratings lowered shares of Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. Zacks Research cut shares of Delcath Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 6th. Finally, Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $29.33.

Delcath Systems Trading Up 35.8%

Shares of NASDAQ:DCTH opened at $20.27 on Tuesday. The stock’s 50-day moving average price is $15.53 and its two-hundred day moving average price is $12.49. Delcath Systems has a 12-month low of $8.12 and a 12-month high of $20.30. The firm has a market cap of $703.37 million, a price-to-earnings ratio of 2,029.03 and a beta of 0.62.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings results on Monday, November 9th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.26. The company had revenue of $35.10 million during the quarter, compared to analysts’ expectations of $25.99 million. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%. As a group, research analysts forecast that Delcath Systems will post -0.17 earnings per share for the current fiscal year.

Institutional Trading of Delcath Systems

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp bought a new stake in shares of Delcath Systems in the 2nd quarter worth about $1,362,000. Russell Investments Group Ltd. lifted its position in shares of Delcath Systems by 31.1% during the third quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company’s stock worth $1,417,000 after purchasing an additional 21,069 shares during the last quarter. Alps Advisors Inc. grew its stake in Delcath Systems by 30.3% in the third quarter. Alps Advisors Inc. now owns 45,640 shares of the company’s stock worth $729,000 after purchasing an additional 10,600 shares in the last quarter. Kopp Family Office LLC bought a new stake in Delcath Systems in the third quarter valued at about $450,000. Finally, Integrated Wealth Concepts LLC bought a new stake in Delcath Systems in the second quarter valued at about $48,000. Institutional investors own 61.12% of the company’s stock.

Key Stories Impacting Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Q3 earnings were $0.17 per share, versus analysts’ expected loss of $0.09, and revenue of $35.1 million exceeded the $26.0 million consensus estimate. Zacks earnings report
• Positive Sentiment: Delcath guided to $115 million–$117 million in 2026 revenue, above the $106.2 million analyst consensus, and said it is targeting at least 36 active centers by year-end. The higher outlook and expansion target point to stronger expected commercial performance. 2026 guidance and active-center target
• Positive Sentiment: BTIG Research raised its price target to $25 from $21 and reiterated a Buy rating, reflecting a more bullish analyst view. BTIG Research rating information

About Delcath Systems

Delcath Systems, Inc is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.

Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company’s proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.

Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand.